'Beyond our expectations': How to invest in obesity drugs like Ozempic with ASX ETFs

This could be your way to invest in obesity drugs.

medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price has come under significant pressure in recent months due to the emergence of obesity drugs.

With analysts forecasting huge growth in demand for drugs like Ozempic over the next decade, there are concerns that ResMed could lose some of its sleep apnoea customer base. That's because research shows that 70% of obstructive sleep apnoea (OSA) patients are obese.

The good news is that most analysts believe this is an overreaction and that there's still a huge market for ResMed to grow into outside any Ozempic impacts.

But what about Ozempic and other obesity drugs? Should we be investing in them as well?

The team at Morgan Stanley believes it could be a good idea based on its expectations for explosive growth through to 2030.

Morgan Stanley's European Biopharmaceuticals analyst, Mark Purcell, commented:

Social media activity documenting transformative weight loss, together with the establishment of affordable insurance coverage more quickly than anticipated, has helped drive demand for obesity medicines beyond our expectations. While supply constraints have capped sales growth in the near term, the global obesity market could go from a $2.4 billion category in 2022 to reach $77 billion in 2030, up from our previous estimate for a $54 billion.

ASX ETFs to the rescue

The simplest way to invest in Ozempic and other obesity drugs is to go directly to the source.

In the case of Ozempic, this would mean investing in Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), which is listed on Wall Street.

As for Mounjaro, a diabetes treatment being repurposed as an obesity drug, it is owned by US pharmaceutical behemoth Eli Lilly And Co (NYSE: LLY).

However, if you're not keen on going down this route, then you could look at ASX ETFs.

The VanEck Global Healthcare Leaders ETF (ASX: HLTH) gives investors access to 50 of the largest international companies from the global healthcare sector. Its holdings include both Eli Lilly & Co and Novo Nordisk.

Alternatively, the BetaShares Global Healthcare ETF – Currency Hedged (ASX: DRUG) could be another way to do it. It is invested in a touch under 70 global healthcare shares, with Eli Lilly & Co and Novo Nordisk making up a total weighting of 12.9% of the portfolio.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Novo Nordisk. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ETFs

A young well-dressed couple at a luxury resort celebrate successful life choices.
ETFs

Buy and hold these fantastic ASX ETFs until 2035

Let's see why these funds could be long term wealth generators.

Read more »

ETF in written in different colours with different colour arrows pointing to it.
ETFs

Invest $1,000 into these world-class ASX ETFs

What makes these funds top options? Let's find out.

Read more »

ETF written on cubes sitting on piles of coins.
ETFs

$10,000 invested in ASIA ETF a year ago is now worth…

Betashares Asia Technology Tigers ETF provides appealing geographic diversification beyond the US.

Read more »

Concept image of a finger hovering in front of a buy and sell button in front og a stockmarket graphic.
ETFs

Show no fear: ASX investors increasingly 'focused on opportunities' amid sharemarket volatility

Nabtrade's director of investor behaviour says there has been a change in mindset among Aussie investors.

Read more »

Father and daughter with hands on a small plant.
ETFs

Focused on growth? Here are 3 ASX ETFs to consider

Growth investors must ignore the current market noise about tariffs and focus on the long-term horizon.

Read more »

Happy young couple saving money in piggy bank.
ETFs

Buy these top ASX ETFs for a passive income boost

These funds could be worth a closer look if you are hunting income from the share market.

Read more »

A couple sitting in their living room and checking their finances.
ETFs

Where to invest your first $1,000 – reliable ASX ETFs

Here are some long term options for first time investors 

Read more »

Man holding a calculator with Australian dollar notes, symbolising dividends.
ETFs

$10,000 invested in CRYP ETF a year ago is now worth…

This exchange-traded fund allows investors to gain exposure to cryptocurrency in a different way.

Read more »